Objective: To assess the efficacy and safety of Melissa officinalis extract using a fixed dose (60 drops/day) in patients with mild to moderate Alzheimer’s disease.
Design: A four month, parallel group, placebo controlled trial undertaken in three centres in Tehran, Iran.
Methods: Patients with mild to moderate Alzheimer’s disease aged between 65 and 80 years (n = 42; 18 women, 24 men) with a score of ≥ 12 on the cognitive subscale of Alzheimer’s disease assessment scale (ADAS-cog) and ≤ 2 on the clinical dementia rating (CDR) were randomised to placebo or fixed dose of Melissa officinalis extract. The main efficacy measures were the change in the ADAS-cog and CDR-SB scores compared with baseline. Side effects were systematically recorded.
Results: At four months, Melissa officinalis extract produced a significantly better outcome on cognitive function than placebo (ADAS-cog: df = 1, F = 6.93, p = 0.01; CDR: df = 1, F = 16.87, p < 0.0001). There were no significant differences in the two groups in terms of observed side effects except agitation, which was more common in the placebo group (p = 0.03).
Conclusions:Melissa officinalis extract is of value in the management of mild to moderate Alzheimer’s disease and has a positive effect on agitation in such patients.
- Alzheimer’s disease herbal medicine
- Melissa officinalis
- ADAS-cog, cognitive subscale of the Alzheimer’s disease assessment scale
- CDR, clinical dementia rating
- CDR-SB, clinical dementia rating sum of the boxes
- LOCF, last observation carried forward procedure
- OC, observed cases
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.